Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China
Compared to EP alone, toripalimab plus EP is cost-effective as first-line treatment in Chinese ES-SCLC patients, particularly when considering genetic stratification and donation policies. The study results provide important reference for China medical insurance policy-making and clinical practice.
Authors
- Zhengxiong Li (ORCID: https://orcid.org/0000-0003-1880-5096)
- Jiaming Zhu (ORCID: https://orcid.org/0009-0003-0176-3069)
- Wen Liu (ORCID: https://orcid.org/8364-8533-8364-8533)
Institutions
- Zhejiang Chinese Medical University (CN)
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-12-04
- DOI
- https://doi.org/10.3389/fpubh.2025.1690043
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00